| 1.06 -0.01 (-0.93%) | 03-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.38 |
1-year : | 1.62 |
| Resists | First : | 1.19 |
Second : | 1.38 |
| Pivot price | 1.06  |
|||
| Supports | First : | 0.99 |
Second : | 0.86 |
| MAs | MA(5) : | 1.05 |
MA(20) : | 1.05 |
| MA(100) : | 1.47 |
MA(250) : | 1.87 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 83.8 |
D(3) : | 83.2 |
| RSI | RSI(14): 49.8 |
|||
| 52-week | High : | 3.68 | Low : | 0.72 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ GDTC ] has closed above bottom band by 48.7%. Bollinger Bands are 89.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 12 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.06 - 1.07 | 1.07 - 1.07 |
| Low: | 1 - 1 | 1 - 1.01 |
| Close: | 1.05 - 1.06 | 1.06 - 1.07 |
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.
Mon, 02 Mar 2026
Interview with the Chairman: CytoMed Therapeutics Ltd. (NASDAQ:GDTC) - The Wall Street Transcript
Fri, 06 Feb 2026
CytoMed Therapeutics And 2 More Penny Stocks With Promising Prospects - simplywall.st
Thu, 05 Feb 2026
CytoMed Therapeutics Strengthens Future with Advanced Therapies - timothysykes.com
Wed, 28 Jan 2026
Cancer cell therapy company hits back at claims about its first human trial - Stock Titan
Wed, 28 Jan 2026
CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress - Yahoo Finance
Tue, 13 Jan 2026
Biotech seeks investor views on share-based access to cell therapy - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 12 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 67.3 (%) |
| Held by Institutions | 0.5 (%) |
| Shares Short | 198 (K) |
| Shares Short P.Month | 27 (K) |
| EPS | -0.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.47 |
| Profit Margin | 0 % |
| Operating Margin | -452.2 % |
| Return on Assets (ttm) | -22.9 % |
| Return on Equity (ttm) | -42.4 % |
| Qtrly Rev. Growth | 101 % |
| Gross Profit (p.s.) | 0.05 |
| Sales Per Share | 0.06 |
| EBITDA (p.s.) | -0.28 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -4.24 |
| PEG Ratio | 0 |
| Price to Book value | 2.2 |
| Price to Sales | 17.03 |
| Price to Cash Flow | -3.95 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|